126 related articles for article (PubMed ID: 7681806)
1. Clinical remission criteria for epithelial carcinoma of the ovary.
Morikawa Y; Kawai M; Kano T; Kikkawa F; Oguchi H; Nakashima N; Ishizuka T; Furuhashi Y; Hattori SE; Kuzuya K
Gynecol Oncol; 1993 Mar; 48(3):342-8. PubMed ID: 7681806
[TBL] [Abstract][Full Text] [Related]
2. [The therapeutic value of second-look laparotomy in advanced ovarian carcinoma].
Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ
Zentralbl Gynakol; 1988; 110(22):1443-8. PubMed ID: 3223119
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of cisplatin, vinblastine, and bleomycin versus cyclophosphamide, aclacinomycin, and cisplatin in epithelial ovarian cancer.
Tokuhashi Y; Kikkawa F; Tamakoshi K; Suganuma N; Kuzuya K; Arii Y; Kawai M; Hattori S; Kobayashi I; Furuhashi Y; Nakashima N; Tomoda Y
Oncology; 1997; 54(4):281-6. PubMed ID: 9216851
[TBL] [Abstract][Full Text] [Related]
4. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study.
Bertelsen K
Gynecol Oncol; 1990 Aug; 38(2):203-9. PubMed ID: 2167280
[TBL] [Abstract][Full Text] [Related]
5. [Effect of chemotherapy on the prognosis of ovarian cancer].
Sugawa T; Umesaki N; Yajima A; Satoh S; Terashima Y; Ochiai K; Tomoda Y; Kanoh T; Noda K; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Sep; 44(9):1135-41. PubMed ID: 1333504
[TBL] [Abstract][Full Text] [Related]
6. Place of second-look laparotomy after 18 courses of chemotherapy in epithelial ovarian cancer.
Ngan HY; Wong LC; Ma HK
Aust N Z J Obstet Gynaecol; 1989 Feb; 29(1):52-4. PubMed ID: 2562603
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of cisplatin and carboplatin versus cisplatin, vinblastine and bleomycin in ovarian cancer.
Kikkawa F; Matsuzawa K; Arii Y; Kawai M; Kobayashi I; Nakashima N; Mizutani S
Gynecol Obstet Invest; 2000; 50(4):269-74. PubMed ID: 11093052
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin based combination chemotherapy in the treatment of stage III ovarian epithelial tumors of low malignant potential.
Yazigi R; Munoz AK; Sandstad J; Lifshitz S; Choi DJ
Eur J Gynaecol Oncol; 1991; 12(6):451-5. PubMed ID: 1809577
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients.
Brower MS; Coleman M; Pasmantier MW; Silver RT; Mamaril AP; Quiguyan CC
Med Pediatr Oncol; 1984; 12(1):17-24. PubMed ID: 6321930
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
[TBL] [Abstract][Full Text] [Related]
11. [The indications for second-look laparotomy in ovarian cancer patients].
Gulo EI; Vinokurov VL; Bokhman IaV
Vopr Onkol; 1992; 38(5):616-23. PubMed ID: 1300762
[TBL] [Abstract][Full Text] [Related]
12. Second-look laparotomy after chemotherapy in the management of ovarian malignancy.
Smirz LR; Stehman FB; Ulbright TM; Sutton GP; Ehrlich CE
Am J Obstet Gynecol; 1985 Jul; 152(6 Pt 1):661-8. PubMed ID: 4040706
[TBL] [Abstract][Full Text] [Related]
13. Whole abdominal and pelvic irradiation in patients with minimal disease at second-look surgical reassessment for ovarian carcinoma.
Hoskins WJ; Lichter AS; Whittington R; Artman LE; Bibro MC; Park RC
Gynecol Oncol; 1985 Mar; 20(3):271-80. PubMed ID: 3972290
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resection.
Barlow JJ; Lele SB; Emrich LJ
Am J Obstet Gynecol; 1985 Jun; 152(3):310-4. PubMed ID: 2988337
[TBL] [Abstract][Full Text] [Related]
15. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
[TBL] [Abstract][Full Text] [Related]
16. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sugiyama T; Kikuchi Y; Suzuki M; Terakawa N
Obstet Gynecol; 2002 Aug; 100(2):281-7. PubMed ID: 12151151
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
Skírnisdóttir I; Lindborg K; Sorbe B
Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
[TBL] [Abstract][Full Text] [Related]
18. Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy.
Sorbe B
Int J Gynecol Cancer; 2003; 13 Suppl 2():192-5. PubMed ID: 14656279
[TBL] [Abstract][Full Text] [Related]
19. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
Zhao D; Wu LY; Wang XB; Li XG
Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
[TBL] [Abstract][Full Text] [Related]
20. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
